[
  {
    "id": "metformin",
    "name": "Metformin",
    "description": "First-line oral biguanide that lowers hepatic glucose production and improves insulin sensitivity.",
    "benefits": ["Durable A1C lowering", "Negligible hypoglycemia or weight gain", "Long-term safety and affordability"],
    "risks": ["GI side effects (minimize with low initial dose)", "Vitamin B12 deficiency with long-term use"],
    "avoidIf": ["advanced_ckd", "gi_intolerance"],
    "preferIf": ["cost_sensitive"],
    "evidence": [
      {
        "id": "m1",
        "source": "Diabetes Canada 2024, Can J Diabetes",
        "quote": "Metformin is recommended as the initial antihyperglycemic medication because of its durable efficacy in lowering A1C, negligible risk for hypoglycemia or weight gain, relatively mild side-effect profile, long-term track record, and affordability."
      }
    ]
  },
  {
    "id": "sglt2",
    "name": "SGLT2 Inhibitor",
    "description": "Oral class that increases urinary glucose excretion and provides heart-kidney protection.",
    "benefits": ["Cardiorenal protection in CKD, HF, and high CV risk", "Weight loss", "Negligible hypoglycemia"],
    "risks": ["Genital mycotic infections", "Volume depletion", "Hold in acute illness; eGFR limits per product"],
    "avoidIf": [],
    "preferIf": ["ckd", "hf", "ascvd"],
    "evidence": [
      {
        "id": "s1",
        "source": "Diabetes Canada 2024, Can J Diabetes",
        "quote": "An SGLT2 inhibitor with demonstrated evidence of benefit is recommended for individuals with CKD (Grade A for canagliflozin, dapagliflozin, or empagliflozin)."
      },
      {
        "id": "s2",
        "source": "CCS 2022, Can J Cardiol",
        "quote": "In adults with HF and LVEF ≤40%, we recommend use of SGLT2i to reduce all-cause and CV mortality, hospitalization for HF, and composite kidney outcome."
      }
    ]
  },
  {
    "id": "glp1",
    "name": "GLP-1 Receptor Agonist",
    "description": "Incretin-based therapy (often injectable) that improves glucose control and supports weight loss.",
    "benefits": ["MACE reduction in high CV risk", "Weight loss", "Negligible hypoglycemia", "Nonfatal stroke reduction"],
    "risks": ["Nausea, vomiting, diarrhea (often transient)", "Avoid in pregnancy; safety unknown"],
    "avoidIf": ["gi_intolerance"],
    "preferIf": ["ascvd", "weight_loss_goal"],
    "evidence": [
      {
        "id": "g1",
        "source": "Diabetes Canada 2024, Can J Diabetes",
        "quote": "A GLP1-RA with demonstrated evidence of benefit is recommended for individuals at high CV risk (dulaglutide, liraglutide, or subcutaneous semaglutide)."
      },
      {
        "id": "g2",
        "source": "CCS 2022, Can J Cardiol",
        "quote": "GLP-1RA to reduce the risk of nonfatal stroke (Strong Recommendation; Moderate-Quality Evidence)."
      }
    ]
  },
  {
    "id": "dpp4",
    "name": "DPP-4 Inhibitor",
    "description": "Oral incretin enhancer with modest glucose lowering and generally low hypoglycemia risk.",
    "benefits": ["Oral dosing", "Low hypoglycemia risk", "Weight neutral"],
    "risks": ["Modest A1C lowering vs GLP-1/SGLT2", "Some agents: heart failure signal in trials"],
    "avoidIf": ["hf"],
    "preferIf": [],
    "evidence": [
      {
        "id": "d1",
        "source": "Diabetes Canada 2024, Can J Diabetes",
        "quote": "Combinations of metformin with ... DPP4 inhibitors have broadly comparable A1C-lowering benefits. DPP4 inhibitors have a neutral effect on weight."
      }
    ]
  },
  {
    "id": "sulfonylurea",
    "name": "Sulfonylurea",
    "description": "Oral insulin secretagogue that lowers glucose effectively but can increase hypo risk.",
    "benefits": ["Effective A1C lowering", "Low cost"],
    "risks": ["Hypoglycemia", "Weight gain (1.5–5 kg)"],
    "avoidIf": ["high_hypoglycemia_risk"],
    "preferIf": ["cost_sensitive"],
    "evidence": [
      {
        "id": "su1",
        "source": "Diabetes Canada 2024, Can J Diabetes",
        "quote": "The risk of hypoglycemia is lower with incretins, SGLT2 inhibitors, and thiazolidinediones compared to sulfonylureas and insulin. Where financial barriers exist, sulfonylureas are the least expensive alternative."
      }
    ]
  },
  {
    "id": "basal_insulin",
    "name": "Basal Insulin",
    "description": "Long-acting insulin replacement used for strong glucose lowering, especially when control is severe.",
    "benefits": ["No dose ceiling; strong glucose lowering", "First-line in metabolic decompensation or severe symptomatic hyperglycemia"],
    "risks": ["Hypoglycemia", "Weight gain", "Injection burden"],
    "avoidIf": ["high_hypoglycemia_risk"],
    "preferIf": ["very_high_a1c"],
    "evidence": [
      {
        "id": "i1",
        "source": "Diabetes Canada 2024, Can J Diabetes",
        "quote": "Insulin, with or without metformin, is recommended as initial pharmacologic therapy for individuals with metabolic decompensation and/or severe symptomatic hyperglycemia."
      }
    ]
  },
  {
    "id": "prednisone",
    "name": "Prednisone (systemic steroid)",
    "description": "Systemic corticosteroid for inflammatory disease; not a diabetes glucose-lowering treatment.",
    "benefits": ["Not a glucose-lowering therapy", "Used for inflammatory disease, not routine T2DM management"],
    "risks": ["Can markedly worsen hyperglycemia", "Fluid retention and blood pressure worsening", "Higher infection risk with prolonged use"],
    "avoidIf": ["ascvd", "hf"],
    "contraindicatedIf": ["ckd", "high_hypoglycemia_risk", "weight_loss_goal"],
    "preferIf": [],
    "unsafeDecoy": true,
    "evidence": [
      {
        "id": "x1",
        "source": "Clinical safety principle",
        "quote": "Systemic corticosteroids are not first-line glucose-lowering treatment and may worsen glycemic control."
      }
    ]
  },
  {
    "id": "ibuprofen_high_dose",
    "name": "Ibuprofen (high-dose chronic)",
    "description": "NSAID analgesic/anti-inflammatory; not used to treat hyperglycemia.",
    "benefits": ["Analgesic/anti-inflammatory only", "No glucose-lowering benefit"],
    "risks": ["Can precipitate AKI and worsen CKD", "GI bleeding risk", "Can worsen blood pressure and fluid status"],
    "avoidIf": ["ckd", "hf"],
    "contraindicatedIf": ["ckd"],
    "preferIf": [],
    "unsafeDecoy": true,
    "evidence": [
      {
        "id": "x2",
        "source": "Clinical safety principle",
        "quote": "Chronic high-dose NSAID therapy is unsafe in CKD and does not treat hyperglycemia."
      }
    ]
  },
  {
    "id": "gentamicin",
    "name": "Gentamicin",
    "description": "Aminoglycoside antibiotic for serious infections; no role in chronic diabetes control.",
    "benefits": ["Antibiotic for selected severe infections", "No role in chronic glucose control"],
    "risks": ["Nephrotoxicity", "Ototoxicity", "Requires therapeutic drug monitoring"],
    "avoidIf": ["ckd"],
    "contraindicatedIf": ["ckd", "ascvd", "hf", "weight_loss_goal", "high_hypoglycemia_risk", "cost_sensitive"],
    "preferIf": [],
    "unsafeDecoy": true,
    "evidence": [
      {
        "id": "x3",
        "source": "Clinical safety principle",
        "quote": "Aminoglycosides are infection-directed agents and can cause serious kidney injury, especially in CKD."
      }
    ]
  },
  {
    "id": "warfarin",
    "name": "Warfarin",
    "description": "Vitamin K antagonist anticoagulant for clot prevention in specific indications, not glucose control.",
    "benefits": ["Anticoagulant for specific thromboembolic indications", "No glucose-lowering effect"],
    "risks": ["Major bleeding risk", "Frequent INR monitoring", "High interaction burden"],
    "avoidIf": ["high_hypoglycemia_risk", "ckd"],
    "contraindicatedIf": ["weight_loss_goal", "cost_sensitive"],
    "preferIf": [],
    "unsafeDecoy": true,
    "evidence": [
      {
        "id": "x4",
        "source": "Clinical safety principle",
        "quote": "Anticoagulation should only be used for clear thrombosis indications and is not treatment for hyperglycemia."
      }
    ]
  }
]
